Herein, we developed and optimized a formulation of target-specific exosomes loaded with Hiltonol (TLR3 agonist) and the ICD inducer human neutrophil elastase (ELANE) [30] to form an in situ DC vaccine for breast cancer treatment. The gene discussed is TLR3; the disease is breast carcinoma.